Q-omics provides the consensus-scored GUCY2D profile across patient tissues and cancer cell-line models. GUCY2D expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GUCY2D is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, GUCY2D RNA expression shows 12,224 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where GUCY2D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCY2D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCY2D survival associations across molecular data types. GUCY2D RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCY2D RNA expression–survival associations across cancer types. High GUCY2D expression shows unfavorable associations in KIRC, UCEC, ACC and LGG, but favorable associations in BRCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GUCY2D RNA expression.
This table summarizes GUCY2D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GUCY2D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCY2D shows higher tumor expression in THCA, LIHC, KIRC, CHOL, BLCA and PRAD. The THCA box plot shows higher GUCY2D RNA expression in tumor versus normal tissue (log2 FC = +0.628, t-test p < 0.001).
This table shows molecular features associated with GUCY2D in patient tissues and cancer cell lines. In patient samples, GUCY2D shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCY2D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
